Jing C Li

US Patent:

6444439, Sep 3, 2002

Filed:

Jan 13, 1998

Appl. No.:

09/006428

Inventors:

Jing Li - Malden MA
Kazuhisa Nishizawa - Brookline MA
Wengian An - Framingham MA
Ellis L. Reinherz - Lincoln MA

Assignee:

Dana-Farber Cancer Institute - Boston MA

International Classification:

C12P 2106

US Classification:

435 691, 4352523, 536 231, 536 235, 530352

Abstract:

A human CD2 cytoplasmic tail binding protein, CD2BP1, is described, as well as the nucleic acids encoding the protein. Also described are expression vectors and recombinant host cells comprising nucleic acids encoding the CD2BP1 protein, and methods of use for the CD2BP1 protein and nucleic acids encoding the CD2BP1 protein.

US Patent:

6689868, Feb 10, 2004

Filed:

Jul 13, 2000

Appl. No.:

09/615387

Inventors:

Jing Li - Lynnfield MA
Kazuhisa Nishizawa - Tokyo, JP
Wenqian An - Wayland MA
Ellis L. Reinherz - Lincoln MA

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C07K 1600

US Classification:

5303879

Abstract:

A human CD2 cytoplasmic tail binding protein, CD2BP1, is described, as well as the nucleic acids encoding the protein. Also described are expression vectors and recombinant host cells comprising nucleic acids encoding the CD2BP1 protein, and methods of use for the CD2BP1 protein and nucleic acids encoding the CD2BP1 protein.

US Patent:

7091330, Aug 15, 2006

Filed:

Jun 1, 2001

Appl. No.:

09/873106

Inventors:

Ellis L. Reinherz - Lincoln MA, US
Christian Freund - Berlin, DE
Jing Li - Lynnfield MA, US
Kazuhisa Nishizawa - Tokyo, JP
Gerhard Wagner - Brookline MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA
President and Fellows of Harvard College - Cambridge MA

International Classification:

C12P 21/02
C12N 15/12

US Classification:

536 235, 435 691, 435325, 4353201

Abstract:

A human CD2 cytoplasmic tail binding protein, CD2BP2, is described, as well as the nucleic acids encoding the protein. Also described are expression vectors and recombinant host cells comprising nucleic acids encoding the CD2BP2 protein, and methods of use for the CD2BP2 protein and nucleic acids encoding the CD2BP2 protein.

US Patent:

7638604, Dec 29, 2009

Filed:

Jun 22, 2004

Appl. No.:

10/873972

Inventors:

Jing Li - Lexington MA, US
Xiang-Yang Tan - Reading MA, US
Kathleen N. Tomkinson - Cambridge MA, US
Debra D. Pittman - Windham NH, US
Geertruida M. Veldman - Sudbury MA, US
Lynette Fouser - Acton MA, US

Assignee:

Genetics Institute, LLC - Cambridge MA

International Classification:

C12P 21/08
A61K 39/395

US Classification:

5303881, 4241451, 435 7021

Abstract:

Antibodies and antigen-binding fragments thereof that bind interleukin-22 (IL-22), in particular, human IL-22, and their uses in regulating IL-22-associated immune responses are disclosed. The antibodies disclosed herein are useful in diagnosing, preventing, or treating IL-22-associated immune disorders, e. g. , autoimmune disorders (e. g. , arthritis).

US Patent:

7901684, Mar 8, 2011

Filed:

Feb 20, 2007

Appl. No.:

11/708061

Inventors:

Davinder S. Gill - Andover MA, US
Jing Li - Lexington MA, US
Geertruida M. Veldman - Sudbury MA, US
Lynette A. Fouser - Acton MA, US
Viia Valge-Archer - Cambridge, GB
David C. Lowe - Hertfordshire, GB
Caroline S. Russell - Hertfordshire, GB
Suzanne E. Cohen - Hertfordshire, GB
Albert G. Thom - Suffolk, GB
Ralph R. Minter - London, GB

Assignee:

Wyeth LLC - Madison NJ
Medimmune Limited - Cambridge

International Classification:

C07K 16/24
A61K 39/395

US Classification:

4241451, 4241301, 4241411, 5303881, 53038815, 53038823, 5303892

Abstract:

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

US Patent:

8182817, May 22, 2012

Filed:

Jan 29, 2010

Appl. No.:

12/696434

Inventors:

Davinder S. Gill - Andover MA, US
Jing Li - Lexington MA, US
Geertruida M. Veldman - Sudbury MA, US
Lynette A. Fouser - Acton MA, US
Viia Valge-Archer - Cambridge, GB
David C. Lowe - Cambridge, GB
Caroline S. Russell - Cambridge, GB
Suzanne E. Cohen - Cambridge, GB
Albert G. Thom - Cambridge, GB
Ralph R. Minter - Cambridge, GB

Assignee:

Wyeth LLC - Madison NJ
Medimmune Limited - Cambridge

International Classification:

C07K 16/24
A61K 39/395

US Classification:

4241451, 4241301, 4241411, 5303881, 53038815, 53038823, 5303892

Abstract:

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

US Patent:

8187603, May 29, 2012

Filed:

May 29, 2009

Appl. No.:

12/474644

Inventors:

Davinder S. Gill - Andover MA, US
Jing Li - Lexington MA, US
Geertruida M. Veldman - Sudbury MA, US
Lynette A. Fouser - Acton MA, US
Viia Valge-Archer - Cambridge, GB
David C. Lowe - Cambridge, GB
Caroline S. Russell - Cambridge, GB
Suzanne E. Cohen - Cambridge, GB
Albert G. Thom - Cambridge, GB
Ralph R. Minter - Cambridge, GB

Assignee:

Wyeth LLC - Madison NJ
MedImmune Limited - Cambridge

International Classification:

C07K 16/24
A61K 39/395

US Classification:

4241451, 4241301, 4241411, 5303881, 53038815, 53038823, 5303892

Abstract:

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

US Patent:

8350059, Jan 8, 2013

Filed:

Dec 8, 2008

Appl. No.:

12/746672

Inventors:

Roch Boivin - North Chelmsford MA, US
Silvio A. Campagna - Candia NH, US
Hong Du - North Andover MA, US
Francis G. Fang - Andover MA, US
Thomas Horstmann - Boston MA, US
Charles-Andre Lemelin - North Chelmsford MA, US
Jing Li - College Station TX, US
Pamela McGuinness - Methuen MA, US
Xiang Niu - Watertown MA, US
Matthew J. Schnaderbeck - Methuen MA, US
Kevin (kuo-ming) Wu - Acton MA, US
Xiaojie (jeff) Zhu - Andover MA, US

Assignee:

Eisai R&D Management Co., Ltd. - Tokyo

International Classification:

C07D 493/00

US Classification:

549270

Abstract:

Disclosed herein are methods and intermediates useful in the preparation of macrolides, e. g. , compounds of formula (IV) wherein R-Rare as defined herein.